secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-09-08T23:59:59+00:00
Accession:  0001493152-25-012769
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA presents Phase 2 THIO-101 poster at WCLC showing PFS improvement in advanced NSCLC
--------------------------------------------------------------------------------

- Poster titled 'Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS' presented at 2025 WCLC on Sept 7, 2025.
- Data from Phase 2 THIO-101 trial evaluating THIO + cemiplimab in advanced NSCLC patients who failed ≥2 prior therapies.
- Specific efficacy numbers (e.g., median PFS, response rates) not disclosed in the filing; poster available on company website Sept 8.
- No safety or additional endpoints described in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225012769/0001493152-25-012769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225012769/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-012769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer